Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $338.4 million.

  • Beam Therapeutics' Total Non-Current Liabilities fell 971.33% to $338.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.4 million, marking a year-over-year decrease of 971.33%. This contributed to the annual value of $364.9 million for FY2024, which is 2329.11% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Total Non-Current Liabilities is $338.4 million, which was down 971.33% from $337.8 million recorded in Q2 2025.
  • Beam Therapeutics' Total Non-Current Liabilities' 5-year high stood at $616.3 million during Q4 2021, with a 5-year trough of $234.0 million in Q1 2021.
  • For the 5-year period, Beam Therapeutics' Total Non-Current Liabilities averaged around $446.8 million, with its median value being $443.4 million (2024).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 34651.84% in 2021, then crashed by 2608.11% in 2024.
  • Over the past 5 years, Beam Therapeutics' Total Non-Current Liabilities (Quarter) stood at $616.3 million in 2021, then fell by 3.34% to $595.8 million in 2022, then fell by 20.16% to $475.7 million in 2023, then decreased by 23.29% to $364.9 million in 2024, then fell by 7.26% to $338.4 million in 2025.
  • Its last three reported values are $338.4 million in Q3 2025, $337.8 million for Q2 2025, and $337.4 million during Q1 2025.